RCS - Faron Pharma. Oy - Faron at Proactive One2One Investor Forum

Faron Pharmaceuticals OyAnnouncement

24/01/2022 07:05

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220124:nRSX2813Za&default-theme=true

RNS Number : 2813Z  Faron Pharmaceuticals Oy  24 January 2022

 

Faron Pharmaceuticals Ltd.

("Faron")

 

Faron to Present at the Proactive One2One Investor Forum

 

Press Release, January 24, 2022 at 02:00 AM (EDT) / 07:00 AM (GMT) / 09:00 AM
(EET)

 

TURKU, FINLAND / BOSTON, MA - Faron Pharmaceuticals Ltd. (AIM: FARN, First
North: FARON), a clinical stage biopharmaceutical company focused on building
the future of immunotherapy by harnessing the power of the immune system to
tackle cancer and inflammation, today announced that Dr. Markku Jalkanen,
Chief Executive Officer of Faron, will participate in the Proactive One2One
Investor Forum, taking place on January 27, 2022.

 

A link to view Dr. Jalkanen's presentation can be found on the "Investors"
section on Faron's website at https://www.faron.com/investors
(https://www.faron.com/investors) .

 

For more information please contact:

 

Media Contact

Faron Pharmaceuticals

Eric Van Zanten

Head of Communications

eric.vanzanten@faron.com (mailto:Eric.vanzanten@faron.com)

Investor.relations@faron.com

Phone: +1 (610) 529-6219

 

Investor Contact

Stern Investor Relations

Julie Seidel

julie.seidel@sternir.com (mailto:Julie.seidel@sternir.com)

Phone: +1 (212) 362-1200

 

Cairn Financial Advisers LLP, Nomad

Sandy Jamieson, Jo Turner

Phone: +44 (0) 207 213 0880

 

Peel Hunt LLP, Broker

Christopher Golden, James Steel

Phone: +44 (0) 20 7418 8900

 

Sisu Partners Oy, Certified Adviser on Nasdaq First North

Juha Karttunen

Phone: +358 (0)40 555 4727

Jukka Järvelä

Phone: +358 (0)50 553 8990

 

Consilium Strategic Communications

Mary-Jane Elliott, David Daley, Lindsey Neville

faron@consilium-comms.com (mailto:faron@consilium-comms.com)

Phone: +44 (0)20 3709 5700

 

About Faron Pharmaceuticals Ltd

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical
company developing novel treatments for medical conditions with significant
unmet needs caused by dysfunction of our immune system. The Company currently
has a pipeline based on the receptors involved in regulation of immune
response in oncology, organ damage and bone marrow
regeneration. Bexmarilimab, a novel anti-Clever-1 humanized antibody, is its
investigative precision immunotherapy with the potential to provide permanent
immune stimulation for difficult-to-treat cancers through targeting myeloid
function. Currently in Phase I/II clinical development as a potential therapy
for patients with untreatable solid tumors, bexmarilimab has potential as a
single-agent therapy or in combination with other standard treatments
including immune checkpoint molecules. Traumakine is an investigational
intravenous (IV) interferon beta-1a therapy for the treatment of acute
respiratory distress syndrome (ARDS) and other ischemic or hyperinflammatory
conditions. Traumakine is currently being evaluated in global trials as a
potential treatment for hospitalized patients with COVID-19 and with the 59th
Medical Wing of the US Air Force and the US Department of Defense for the
prevention of multiple organ dysfunction syndrome (MODS) after
ischemia-reperfusion injury caused by a major trauma.  Faron is based
in Turku, Finland. Further information is available at www.faron.com
(http://www.faron.com/) .

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAGZGZMKMMGZZM